Influence of renal impairment on the pharmacokinetics of oral roflumilast: An open-label, parallel-group, single-center study

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 8, 2011, Pages 491-499

  Bethke, T D ^a   Hartmann, M ^a   Hunnemeyer A ^a   Lahu, G ^a   Gleiter, C H ^b  

^a Nycomed GmbH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Human; Pharmacokinetics; Renal impairment; Roflumilast

Indexed keywords

ALLOPURINOL; CALCIUM CARBONATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PARACETAMOL; PHOSPHATE BINDING AGENT; PHOSPHODIESTERASE INHIBITOR; ROFLUMILAST; ROFLUMILAST N OXIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PROSPECTIVE STUDY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AMINOPYRIDINES; AREA UNDER CURVE; BENZAMIDES; CASE-CONTROL STUDIES; CREATININE; CYCLOPROPANES; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX;

EID: 80052208536     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201556     Document Type: Article

References (24)

1. Bethke TD, Lahu G. High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast. Int J Clin Pharmacol Ther. 2011; 49: 51-57. PubMed
2. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 2001; 297: 280-290. PubMed
3. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001; 297: 267-279. PubMed
4. Hermann R, Nassr N, Lahu G, Péterfai E, Knoerzer D, Herzog R, Zech K, de Mey C. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet. 2007; 46: 403-416. PubMed doi: 10.2165/00003088-200746050-00003
5. Nycomed. Data on file.
6. Bethke T, Hartmann M, Zech K, David M, Weimar C, Wurst W. No dose adjustment of roflumilast in patients with severe renal impairment [abstract]. Am J Respir Crit Care Med. 2002; 65: A594.
7. Food and Drug Administration. Guidance for Industry Drug: Pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. Rockville, MD: US Department of Health and Human Services; 1998.
8. Reidenberg MM, Drayer DE. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet. 1984; 9 (Suppl 1): 18-26. doi:10.2165/00003088- 198400091-00003 PubMed
9. Lam YW, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet. 1997; 32: 30-57. doi: 10.2165/00003088-199732010-00002 PubMed
10. Okabe H, Hasunuma M, Hashimoto Y. The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction. Pharm Res. 2003; 20: 1591-1594. doi:10.1023/A:1026131216669 PubMed
11. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008; 83: 898-903. doi:10.1038/clpt.2008.59 PubMed
12. Bethke TD, Böhmer GM, Hermann R, Hauns B, Fux R, Mörike K, David M, Knoerzer D, Wurst W, Gleiter CH. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol. 2007; 47: 26-36. doi:10.1177/0091270006294529 PubMed
13. Bethke TD, Hauns B, Zech K, David M, Wurst W. Dose linearity of roflumilast, a new selective PDE4 inhibitor [abstract]. Am J Respir Crit Care Med. 2002; 165: A595.
14. Seyffart G. Introduction. Drug Dosage in Renal Insufficiency. Dordrecht: Kluwer; 1991.
15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604-612. PubMed
16. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009; 65: 757-773. doi:10.1007/s00228-009-0678-8 PubMed
17. Kappel J, Calissi P. Nephrology: 3. Safe drug prescribing for patients with renal insufficiency. CMAJ. 2002; 166: 473-477. PubMed
18. Dettli L. Multiple dose elimination kinetics and drug accumulation in patients with normal and with impaired kidney function. Adv Biosci. 1969; 5: 39-54.
19. Tett SE, Kirkpatrick CM, Gross AS, McLachlan AJ. Principles and clinical application of assessing alterations in renal elimination pathways. Clin Pharmacokinet. 2003; 42: 1193-1211. doi:10.2165/00003088-200342140-00002 PubMed
20. European Agency for the Evaluation of Medicinal Products (EMEA). COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP). Note for guidance on the evaluation of the PK of medicinal products in patients with impaired renal function. London: CHMP/EWP/225/02; 2004.
21. Boxenbaum H, Tannenbaum S, Mayersohn M, Oleson F. Pharmacokinetics tricks and traps: drug dosage adjustment in renal failure. J Pharm Pharm Sci. 1999; 2: 2-4. PubMed
22. Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin North Am. 2005; 89: 649-687. doi:10.1016/j.mcna.2004.11.007 PubMed
23. Rowland M, Tozer T. N. Clinical pharmacokinetics: Concepts and applications. Philadelphia, PA: Lippincott Williams & Wilkins; 1995.
24. Bauer L. A. Applied clinical pharmacokinetics. New York: McGraw-Hill; 2008.